Skip to main content
Erschienen in: Annals of Nuclear Medicine 12/2022

10.10.2022 | Original Article

The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer

verfasst von: Gozde mutevelızade, Nazım Emrah Kocer, Mehmet Reyhan

Erschienen in: Annals of Nuclear Medicine | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to investigate immunohistochemical staining of sodium iodide symporter (NIS) and its effect on response to I-131 therapy in differentiated thyroid carcinoma patients.

Methods

We evaluated NIS expression, the intracellular distribution of NIS, iodine-131 uptake in residual tissues on post-ablation I-131 whole body scan, and the ablation status after 100 mCi I-131 therapy. We also investigated NIS expression and localization in tumoral paraffin-embedded tissues.

Results

In this retrospective study, 35 patients (mean age 44.17 ± 12.9 years, 27 female, 8 male) were studied. Twenty-one of these patients responded to radioiodine therapy, and 14 did not. NIS expression and iodine-131 uptake in residual tissues post-ablation I-131 whole body scan were not statistically significant. When we compared the patients who responded to radioiodine therapy and the poor responder group, NIS expression and iodine-131 uptake in residual tissues did not demonstrate statistically significant difference [(p = 0.308) (p = 0.985) respectively]. 47.6% of the patients in the successful ablation group and 85.7% in the unsuccessful ablation group had intracellular NIS immunostaining. The difference was not statistically significant (p = 0.139). 52.4% of the patients in the successful ablation group and 7% in the unsuccessful ablation group had NIS immunostaining at the basolateral membrane. The difference was statistically significant (p < 0.05).

Conclusions

In conclusion, we did not find any significant difference between successful and unsuccessful ablation groups in terms of NIS expression; however, we concluded that the intracellular (cytoplasmic) localization of NIS is one of the leading causes of ablation failure regardless of NIS expression in DTC patients.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. CrossRefPubMed
2.
Zurück zum Zitat Weetman AP, Jameson JL. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Disorders of the thyroid gland Harrison’s Principles of Internal Medicine. 15th ed. New York: The McGraw Hill Companies; 2001. p. 2060–84. Weetman AP, Jameson JL. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Disorders of the thyroid gland Harrison’s Principles of Internal Medicine. 15th ed. New York: The McGraw Hill Companies; 2001. p. 2060–84.
3.
Zurück zum Zitat Hussain HK, Britton KE, Grossman AB, Reznek RH. In: Husband JE, Reznek RH, editors. Thyroid cancer. Imaging in Oncology. 2nd ed. London: Taylor and Francis; 2004. p. 669–709. Hussain HK, Britton KE, Grossman AB, Reznek RH. In: Husband JE, Reznek RH, editors. Thyroid cancer. Imaging in Oncology. 2nd ed. London: Taylor and Francis; 2004. p. 669–709.
4.
Zurück zum Zitat Amdur RJ, Mazzaferri EL. İncidence, prevalence, recurrence, and mortality of differentiated thyroid cancer. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 123–30. CrossRef Amdur RJ, Mazzaferri EL. İncidence, prevalence, recurrence, and mortality of differentiated thyroid cancer. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 123–30. CrossRef
5.
Zurück zum Zitat Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol. 2002;57:559–74. CrossRef Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol. 2002;57:559–74. CrossRef
6.
Zurück zum Zitat Mazzaferri EL, Amdur RJ. Thyroid and parathyroid physiology. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 7–17. CrossRef Mazzaferri EL, Amdur RJ. Thyroid and parathyroid physiology. In: Amdur RJ, Mazzaferri EL, editors. Essentials of Thyroid Cancer Management. New York: Springer Science; 2005. p. 7–17. CrossRef
7.
Zurück zum Zitat Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. Na +/I - symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab. 1998;83:4102–6. PubMed Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. Na +/I - symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab. 1998;83:4102–6. PubMed
8.
Zurück zum Zitat Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol. 2009;160:215–25. CrossRefPubMed Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol. 2009;160:215–25. CrossRefPubMed
9.
Zurück zum Zitat Shen DH, Kloos RT, Mazzaferri EL, Jhiang SM. Sodium iodide symporter in health and disease. Thyroid. 2001;11:415–25. CrossRefPubMed Shen DH, Kloos RT, Mazzaferri EL, Jhiang SM. Sodium iodide symporter in health and disease. Thyroid. 2001;11:415–25. CrossRefPubMed
10.
Zurück zum Zitat Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–57. CrossRefPubMed Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999;141:443–57. CrossRefPubMed
11.
Zurück zum Zitat Jhiang SM, Sipos JA. Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. Endocr Relat Cancer. 2021;28(10):T167–77. CrossRefPubMedPubMedCentral Jhiang SM, Sipos JA. Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy. Endocr Relat Cancer. 2021;28(10):T167–77. CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63. CrossRefPubMed Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63. CrossRefPubMed
13.
Zurück zum Zitat Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targetting for cancer therapeutics. Pharmacol Ther. 2012;135:355–70. CrossRefPubMedPubMedCentral Kogai T, Brent GA. The sodium iodide symporter (NIS): regulation and approaches to targetting for cancer therapeutics. Pharmacol Ther. 2012;135:355–70. CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cai X, Wang R, Tan J, Meng Z, Li N. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer. Clin Transl Oncol. 2021;23(12):2403–14. CrossRefPubMed Cai X, Wang R, Tan J, Meng Z, Li N. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer. Clin Transl Oncol. 2021;23(12):2403–14. CrossRefPubMed
15.
Zurück zum Zitat Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45. CrossRefPubMed Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001;28:639–45. CrossRefPubMed
16.
Zurück zum Zitat Morari EC, Marcello MA, Guilhen ACT, Cunha LL, Latuff P, Soares FA, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol. 2011;75:247–54. CrossRef Morari EC, Marcello MA, Guilhen ACT, Cunha LL, Latuff P, Soares FA, et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol. 2011;75:247–54. CrossRef
17.
Zurück zum Zitat Ward LS, Santarosa PL, Granja F, Assumpção LVM, Savoldi M, Goldman GH. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett. 2003;200:85–91. CrossRefPubMed Ward LS, Santarosa PL, Granja F, Assumpção LVM, Savoldi M, Goldman GH. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett. 2003;200:85–91. CrossRefPubMed
18.
Zurück zum Zitat Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab. 2001;86(11):5627–32. CrossRefPubMed Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab. 2001;86(11):5627–32. CrossRefPubMed
19.
Zurück zum Zitat Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer. 2020;27(5):R113–32. CrossRefPubMed Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer. 2020;27(5):R113–32. CrossRefPubMed
20.
Zurück zum Zitat Sodré AKMB, Rubio IGS, Galrão ALR, Knobel M, Tomimori EK, Alves VAF, et al. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab. 2008;93:4141–5. CrossRefPubMed Sodré AKMB, Rubio IGS, Galrão ALR, Knobel M, Tomimori EK, Alves VAF, et al. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab. 2008;93:4141–5. CrossRefPubMed
21.
Zurück zum Zitat Dohan O, Carrasco N. Advances in Na +/I − symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2003;213:59–70. CrossRefPubMed Dohan O, Carrasco N. Advances in Na +/I symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2003;213:59–70. CrossRefPubMed
22.
Zurück zum Zitat Dohán O, Baloch Z, Bánrévi Z, Livolsi V, Carrasco N. Predominant intracellular overexpression of the Na +/I - Symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001;86(6):2697–700. PubMed Dohán O, Baloch Z, Bánrévi Z, Livolsi V, Carrasco N. Predominant intracellular overexpression of the Na +/I - Symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab. 2001;86(6):2697–700. PubMed
23.
Zurück zum Zitat Kogai T, Endo T, Saito T, Miyazakia A, Kawaguchia A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology. 1997;138:2227–32. CrossRefPubMed Kogai T, Endo T, Saito T, Miyazakia A, Kawaguchia A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology. 1997;138:2227–32. CrossRefPubMed
24.
Zurück zum Zitat Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem. 2001;276(24):21458–63. CrossRefPubMed Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem. 2001;276(24):21458–63. CrossRefPubMed
25.
Zurück zum Zitat Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The association between radioiodine refractory in papillary thyroid carcinoma, sodium/iodide symporter expression, and BRAF V600E mutation. Onco Targets Ther. 2021;14:3959–69. CrossRefPubMedPubMedCentral Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The association between radioiodine refractory in papillary thyroid carcinoma, sodium/iodide symporter expression, and BRAF V600E mutation. Onco Targets Ther. 2021;14:3959–69. CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52(6):765–73. CrossRef Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52(6):765–73. CrossRef
27.
Zurück zum Zitat Smith VE, Sharma N, Watkins RJ, Read ML, Ryan GA, Kwan PP, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab. 2013;98(7):2876–86. CrossRefPubMedPubMedCentral Smith VE, Sharma N, Watkins RJ, Read ML, Ryan GA, Kwan PP, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab. 2013;98(7):2876–86. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Zhao Z, Huang R, Cai H, Liu B, Zeng Y, Kuang A. Improved radioiodine-131 imaging of prostatic carcinoma using the sodium iodide symporter gene under control of the survivin promoter. Int J Clin Exp Pathol. 2018;11(8):4067–72. PubMedPubMedCentral Zhao Z, Huang R, Cai H, Liu B, Zeng Y, Kuang A. Improved radioiodine-131 imaging of prostatic carcinoma using the sodium iodide symporter gene under control of the survivin promoter. Int J Clin Exp Pathol. 2018;11(8):4067–72. PubMedPubMedCentral
29.
Zurück zum Zitat Son SH, Gangadaran P, Ahn BC. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake and cytotoxicity. Int J Nanomedicine. 2019;14:1779–87. CrossRefPubMedPubMedCentral Son SH, Gangadaran P, Ahn BC. A novel strategy of transferring NIS protein to cells using extracellular vesicles leads to increase in iodine uptake and cytotoxicity. Int J Nanomedicine. 2019;14:1779–87. CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, et al. Reintroducing the sodium-iodide symporter to anaplastic thyroid carcinoma. Thyroid. 2017;27(12):1534–43. CrossRefPubMed Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, et al. Reintroducing the sodium-iodide symporter to anaplastic thyroid carcinoma. Thyroid. 2017;27(12):1534–43. CrossRefPubMed
31.
Zurück zum Zitat Spitzweg C, Nelson PJ, Wagner E, Bartenstein P, Weber WA, Schwaiger M, et al. The sodium iodide symporter (NIS) novel applications for radionuclide imaging and treatment. Endocr Relat Cancer. 2021;28:193–213. CrossRef Spitzweg C, Nelson PJ, Wagner E, Bartenstein P, Weber WA, Schwaiger M, et al. The sodium iodide symporter (NIS) novel applications for radionuclide imaging and treatment. Endocr Relat Cancer. 2021;28:193–213. CrossRef
Metadaten
Titel
The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer
verfasst von
Gozde mutevelızade
Nazım Emrah Kocer
Mehmet Reyhan
Publikationsdatum
10.10.2022
Verlag
Springer Nature Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 12/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01794-w

Weitere Artikel der Ausgabe 12/2022

Annals of Nuclear Medicine 12/2022 Zur Ausgabe